Stocktoria
Acrivon Therapeutics, Inc. ACRV
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-11-15
Acrivon Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $60.0M | $64.0M | $46.0M | $23.9M | — |
| Operating income | -$84.1M | -$89.2M | -$67.1M | -$32.7M | -$16.2M |
| Income tax | $0 | — | — | — | — |
| Net income | -$77.9M | -$80.6M | -$60.4M | -$31.2M | -$16.2M |
| EPS (diluted) | $-2.02 | $-2.38 | $-2.74 | $-7.56 | $-9.32 |
| Operating cash flow | -$63.7M | -$65.7M | -$42.6M | -$30.1M | -$14.0M |
| Free cash flow | -$65.3M | -$68.4M | -$43.9M | -$32.3M | -$14.2M |
| Cash & equivalents | $41.5M | $39.8M | $36.0M | $29.5M | $99.6M |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M |
| Total liabilities | $17.2M | $19.8M | $17.1M | $10.8M | $7.9M |
| Shareholders' equity | $112.5M | $176.8M | $121.2M | $170.5M | -$23.8M |
Source: SEC EDGAR filings · CIK 0001781174 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.